Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis

Affiliations

¹ University of California, San Francisco, San Francisco, CA. stephen.hauser@ucsf.edu
² F. Hoffmann–La Roche, Basel, Switzerland
³ University Hospital Basel, Basel, Switzerland

Comment

Stephen L Hauser et al. N Engl J Med. 2017.

. 2017 Apr 27;376(17):1694.

doi: 10.1056/NEJMc1702076.

¹ University of California, San Francisco, San Francisco, CA. stephen.hauser@ucsf.edu
² F. Hoffmann–La Roche, Basel, Switzerland
³ University Hospital Basel, Basel, Switzerland

No abstract available

Comment on

Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis.
Schoergenhofer C, Jilma B. Schoergenhofer C, et al. N Engl J Med. 2017 Apr 27;376(17):1693. doi: 10.1056/NEJMc1702076. N Engl J Med. 2017. PMID: 28445662 No abstract available.
Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis.
Mildiner S, Malnick S. Mildiner S, et al. N Engl J Med. 2017 Apr 27;376(17):1692-3. doi: 10.1056/NEJMc1702076. N Engl J Med. 2017. PMID: 28447770 No abstract available.
Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis.
Deisenhammer F, Auer M, Hegen H. Deisenhammer F, et al. N Engl J Med. 2017 Apr 27;376(17):1693-4. doi: 10.1056/NEJMc1702076. N Engl J Med. 2017. PMID: 28447771 No abstract available.